Its called a "reasonable doubt" from a health professional point of view. Cannapil is indicated for refractory epilepsy and is only available at St Vincent Hospital as far as I know. Will there be more than HUNDREDS of patients admit to St Vincent with REFRACTORY epilepsy? this is where people need to exercise critical thinking on.
I am not saying its definitely a lie. But I am also speaking from an accounting point of view, IF its a real script and got filled by the patient, it will be realised as "revenue" straight away. Revenue is realised when the service/products are provided, NOT when the patients pay. Ask your accountant if you dont understand this accounting concept.
Again, Cannapil is NOT the only MM products available and there are a lot other bigger MM companies and cheaper MM products around. As far as I know, Medlab and Atlea are doing really well in Australia. There is no any exclusiveness about MXC product in my opinion compared to the others.
Since I only practice in Australia so I can only frankly telling people what I know in Australia. (or you can also ask your local GP or pharmacists) In other words, its true that I am not entirely sure whats happened in UK. So its left to investors to make their critical thinking/judgement.
